Valentis licenses delivery technology to Juvaris BioTherapeutics for therapeutic vaccines
The non-exclusive licensing deal gives Juvaris BioTherapeutics access to Valentis’ proprietary plasmid backbone and cationic lipid delivery technologies "for the development and commercialization of therapeutic vaccine products."
Juvaris will assume responsibility for the development, manufacturing and commercialization of products and the associated expenses.
Chairman, President & CEO of Valentis, Benjamin F. McGraw, III, revealed that Valentis was "investing its resources" in a "promising Del-1 angiogenesis product, soon to begin Phase II clinical trials."
While Juvaris will use the proprietary lipid-DNA complexes to up-regulate the immune system and as a delivery platform for antigens, Martin Cleary, President and CEO of Juvaris, acknowledged that the Valentis technology had "been in clinical studies for gene therapy," and added: "this know-how will shorten our time to the clinic and avoid having to start the process from scratch."
Keywords : Valentis Juvaris BioTherapeutics Delivery technology Therapeutic vaccine Gene therapy Development Manufacturing
